Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Killa headshot

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Sweta Killa

Sector ETF report for PBE

Zacks Equity Research

QIAGEN Partners With Novartis to Expand CDx Tests Suite

by Zacks Equity Research

QIAGEN (QGEN) progresses well with the strategy to expand through strategic collaborations. The latest tie up will boost the company's companion diagnostic portfolio.

Zacks Equity Research

QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach

by Zacks Equity Research

The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.

Zacks Equity Research

QIAGEN's New Offerings to Broaden Hematology Testing Suite

by Zacks Equity Research

QIAGEN (QGEN) continues to progress with test menu expansion.

Zacks Equity Research

Qiagen (QGEN) Down 3.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Pacific Biosciences Offers Insights on Aedes aegypti Genome

by Zacks Equity Research

Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.

Zacks Equity Research

Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y

by Zacks Equity Research

Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.

Zacks Equity Research

Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences

by Zacks Equity Research

Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.

Zacks Equity Research

QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q3

by Zacks Equity Research

QIAGEN's (QGEN) year-over-year revenue growth in Q3 and operating margin expansion are encouraging.

Zacks Equity Research

Qiagen (QGEN) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 6.06% and -1.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?